Cyprium Therapeutics, Inc. and Sentynl Therapeutics, Inc., a U.S.-based specialty pharma company owned by the Zydus Group, executed an agreement to acquire Cyprium’s rights to CUTX-101, its Copper Histidinate product candidate for the treatment of Menkes disease.   Sentynl will pay $20 million in upfront and regulatory milestones through NDA approval, as well as potential sales milestones plus royalties based on CUTX-101 sales. Cyprium will be responsible for development of CUTX-101 through ap...